Neomatrix was granted 258.751,70 for a Research Project on Breast Cancer.
12 February 2024–
VAP (Vaccine Ad Personam) aims to establish a new therapy based on Neomatrix technology in the context of breast cancer. In order to understand the feasibility of this innovative therapeutic approach, Neomatrix has entered into collaboration with Professor Silvia Piconese to perform molecular and immunological characterizations in the complex context of breast cancer. In particular, we aim to target the most challenging condition, namely triple-negative breast cancer.
These patients are the most difficult to treat because they test negative for the markers approved for other subclasses of these tumors. The collaboration brings together the excellence of academic research with emerging technology in the world of vaccines that is synthetic biology. This is the only approach that offers the possibility of transforming genomic information relevant to the patient into an effective drug, quickly and at costs manageable by the national health system.